Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma

Abstract

The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.

1 .- 6 . (canceled) 
     
     
         7 . An article of manufacture comprising
 a) a bispecific antibody in a pharmaceutically acceptable carrier comprising wherein the antibody comprises a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3ε (CD3), wherein said first binding part comprises a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR1L region of SEQ ID NO:27, a CDR2L region of SEQ ID NO:28 and a CDR3L region of SEQ ID NO:20;   b) an immunotherapeutic drug in a pharmaceutically acceptable carrier wherein the drug is selected from the group consisting of thalidomide or an immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody; and,   c) instructions for administering said bispecific antibody and said immunotherapeutic drug to a subject in need of a treatment for multiple myeloma.   
     
     
         8 . The article of manufacture according to  claim 7 , wherein the immunotherapeutic drug is selected from the group consisting of daratumumab, isatuximab, MOR202, Ab79, Ab19, thalidomide, lenalidomide, pomalidomide, CC-122, CC-220, pembrolizumab, pidilizumab, nivolumab, MEDI-0680, PDR001, REGN2810, lambrolizumab, MDX-1106, BGB-108, h409A11, h409A16, h409A17, atezolizumab, avelumab, durvalumab, and MDX-1105. 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . The article of manufacture according to  claim 8  wherein:
 a) the instructions specify that the bispecific antibody and the immunotherapeutic drug are administered separately; or 
 b) the instructions specify that the bispecific antibody and the immunotherapeutic drug are administered together. 
 
     
     
         12 . The article of manufacture according to  claim 11  wherein the instructions specify that the bispecific antibody and the immunotherapeutic drug are administered by different administration routes or according to different treatment schedules. 
     
     
         13 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is daratumumab. 
     
     
         14 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is isatuximab. 
     
     
         15 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is MOR202. 
     
     
         16 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is Ab79. 
     
     
         17 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is Ab19. 
     
     
         18 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is thalidomide. 
     
     
         19 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is lenalidomide. 
     
     
         20 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is pomalidomide. 
     
     
         21 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is CC-122. 
     
     
         22 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is CC-220. 
     
     
         23 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is pembrolizumab. 
     
     
         24 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is pidilizumab. 
     
     
         25 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is nivolumab. 
     
     
         26 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is MEDI-0680. 
     
     
         27 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is PDR001. 
     
     
         28 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is REGN2810. 
     
     
         29 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is lambrolizumab. 
     
     
         30 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is MDX-1106. 
     
     
         31 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is BGB-108. 
     
     
         32 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is h409A11. 
     
     
         33 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is h409A16. 
     
     
         34 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is h409A17. 
     
     
         35 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is atezolizumab. 
     
     
         36 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is avelumab. 
     
     
         37 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is durvalumab. 
     
     
         38 . The article of manufacture according to  claim 11  wherein the immunotherapeutic drug is MDX-1105.